Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice
Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan.
|Organiser||European School of Urology (ESU)|
|Duration||Approx. 50 minutes|
Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation. The aims of this UROwebinar are to review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients.
Topic: Prostate cancer
CME: An application for this webinar has been submitted
Duration: Approx. 45 – 60 minutes
Contact our organiser
European School of Urology (ESU)